

**REMARKS**

Applicants have amended the Title of the Specification to correct minor typographical errors.

The IDS is provided to mention two "A" references cited in the IPER that were not mentioned in the PTO-1449 that was filed upon entry of this application into the US National Phase. This RCE is filed to allow submission of the IDS and PTO-1449.

**CONCLUSION**

It is respectfully asserted that in view of the amendments and remarks made above, the case is now in condition for allowance. A Notice of Allowance is respectfully requested.

If any minor issues remain precluding such allowance, the Examiner is requested to contact Applicants' representative at the number below.

Respectfully submitted,

/James P. Riek/

---

James P. Riek  
Attorney for Applicants  
Registration No. 39,009

Date: 4-22-2009  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8022  
Facsimile: (919) 483-7988